Clinical trials using irinotecan

J Pediatr Hematol Oncol. 2002 Feb;24(2):84-5. doi: 10.1097/00043426-200202000-00002.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Agents, Phytogenic / pharmacology
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Camptothecin / pharmacology
  • Camptothecin / therapeutic use*
  • Child
  • Chromosome Breakage
  • Clinical Trials as Topic
  • DNA Damage*
  • DNA Replication / drug effects
  • DNA Topoisomerases, Type I / metabolism
  • DNA, Neoplasm / drug effects*
  • Drug Administration Schedule
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Irinotecan
  • Mice
  • Multicenter Studies as Topic
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neuroblastoma / drug therapy
  • Neuroblastoma / enzymology
  • Neuroblastoma / genetics
  • Rhabdomyosarcoma / drug therapy
  • Rhabdomyosarcoma / enzymology
  • Rhabdomyosarcoma / genetics
  • Topoisomerase I Inhibitors*
  • Topotecan / pharmacology
  • Topotecan / therapeutic use
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents, Phytogenic
  • DNA, Neoplasm
  • Enzyme Inhibitors
  • Neoplasm Proteins
  • Topoisomerase I Inhibitors
  • Irinotecan
  • Topotecan
  • DNA Topoisomerases, Type I
  • Camptothecin